Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow down

ETI reduces pathogen detection rates in respiratory samples, yet a significant proportion of pwCF continue to harbour hallmark pathogens putting them at risk of more rapid decline in lung function https://bit.ly/3DAcKKH.

• Schütz, K.
• Pallenberg, S. T.
• Rosenboom, I.
• Dittrich, A. M.